SNS-314
Potent and Selective Inhibitor of Aurora Kinases A, B, and C for Advanced Solid Tumors
SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. See the SNS-314 mechanism of action.
SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumors. Preclinical studies suggest that SNS-314 can be productively combined with standard chemotherapeutic agents, and combination trials are also anticipated. SNS-314 was discovered at Sunesis.
SNS-314 Presentations
SNS-314, A POTENT INHIBITOR OF AURORA KINASES, HAS PRECLINICAL ANTI-TUMOR ACTIVITY AND INDUCES APOPTOSIS2008 AACR Annual Meeting
San Diego, CA
April 16th, 2008
SNS-314, a selective Aurora kinase inhibitor with potent, preclinical anti-tumor activity shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agentsECCO 14 - European Cancer Conference(x3)
Barcelona, Spain
September 24, 2007 2:00 PM - 5:00 PM
Nonclinical pharmacokinetics, distribution, and excretion of SNS-314, a novel, selective Aurora kinase inhibitorECCO 14 - European Cancer Conference(x3)
Barcelona, Spain
September 24, 2007 2:00 PM - 5:00 PM
Get general information about clinical studies, and learn about Sunesis investigational drugs currently in clinical trial.
Sunesis researchers rely on science to target new and important ways of treating cancer.
Copyright © Sunesis Pharmaceuticals, Inc. 2007. All Rights Reserved.